Optra Hfa Inhaler

Description

Optra Hfa Inhaler

Optra Hfa Inhaler (Ipratropium bromide) Inhaler is a pressurized metered dose Inhaler that delivers 20mcg ipratropium bromide per actuation into the mouth piece of a specially designed actuator. Optra Hfa Inhaler (Ipratropium bromide) contains HFA 134a as propellant and does not contain any chlorofluorocarbons. Ipratropium bromide is a synthetic quaternary ammonium compound, chemically related to atropine. Optra Hfa Inhaler is chemically described as (1R,3r,5S,8r)-3-[[(2RS)-3-Hydroxy-2- phenylpropanoyl]oxy]-8-methyl-8-(1-methylethyl)- 8- azoniabicyclo[3.2.1]octane bromide monohydrate. Its molecular formula is C20H30BrNO3.H2O. Optra Hfa Inhaler Use For Maintenance Treatment Only Ipratropium bromide is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. Ocular Effects Optra Hfa Inhaler is an anticholinergic and its use may increase intraocular pressure. This may result in precipitation or worsening of narrow-angle glaucoma. Therefore, it should be used with caution in patients with narrow-angle glaucoma. Patients should avoid spraying ipratropium bromide inhaler into the eye. – Administration of Optra Hfa Inhaler with beta-adrenergics and xanthine preparations may intensify the bronchodilator effect. – Co-administration of ipratropium bromide with other anticholinergic drugs should be avoided, as this may lead to an increase in anticholinergic adverse effects

Uses

This medicine is used for the prevention and treatment of shortness of breath in patients with Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis and mild to moderate asthma.

 Side effects

Patients administered with this medication may experience headache, dizziness, throat irritation, cough, dry mouth, and nausea. Patients may also experience constipation, urinary retention (inability to urinate completely), occasional paradoxical bronchospasm (narrowing or spasm of airway), tachycardia (increased heart rate), and arrhythmias (disorder of heart rhythm)

When not use

This medication is contraindicated in case of hypersensitivity to the active substance i.e. ipratropium bromide or to atropine.